Loading...

Nachrichtenliste

HR+ Innovative treatment for Breast cancer! Astrazeneca's next generation estrogen receptor depressant camizestrant phase 3 clinical efficacy is remarkable!

2022-10-28


HR+ Innovative treatment for Breast cancer! Astrazeneca's next generation estrogen receptor depressant camizestrant phase 3 clinical efficacy is remarkable!

AstraZeneca (AstraZeneca) recently reported positive, high-level results from its phase II trial of SERENA 2. This is a randomized, open label, parallel group, multicenter phase 2 trials, is a large-scale clinical part of the project, the project focused on camizestrant, this is a kind of powerful next-generation purely oral JiangXieJi selective estrogen receptor and estrogen receptor alpha blockers and are being developed as a single-agent therapy or combined with other drugs, To address an unmet medical need in the field of hormone receptor-positive breast cancer

Wir möchten Cookies verwenden, um Ihre Nutzung dieser Website besser zu verstehen und Ihre Erfahrung bei zukünftigen Besuchen der Website zu verbessern. Sie können diese Einstellung in Ihren Browsereinstellungen ändern. Weitere Informationen zur Verwendung von Cookies finden Sie in unserer Datenschutzrichtlinie.